Brain tumor enhancement in magnetic resonance imaging: Dependency on the level of protein binding of applied contrast agents

Investigative Radiology

Volumn 44, Issue 2, 2009, Pages 89-94

  Wintersperger, Bernd J ^a,b   Runge, Val M ^b   Tweedle, Michael F ^c   Jackson, Carney B ^d   Reiser, Maximilian F ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c Bracco Research USA   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Brain neoplasms; Contrast enhancement; Gadobenate dimeglumine gadopentetate dimeglumine, B22956 1; Gadolinium; Magnetic resonance imaging; Protein binding

Indexed keywords

B 22956 1; BRU 52; GADOBENATE DIMEGLUMINE; GADOCOLETIC ACID TRISODIUM; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; UNCLASSIFIED DRUG; CONTRAST MEDIUM; NERVE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG PROTEIN BINDING; GLIOMA; HISTOPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TUMOR MODEL; ANIMAL; BRAIN TUMOR; DOSE RESPONSE; FISCHER 344 RAT; IMAGE ENHANCEMENT; IMAGE QUALITY; METABOLISM; METHODOLOGY; PATHOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ANIMALS; BRAIN NEOPLASMS; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOMA; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; NERVE TISSUE PROTEINS; RADIOGRAPHIC IMAGE ENHANCEMENT; RATS; RATS, INBRED F344; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 66149138752     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e318191a334     Document Type: Article

References (33)

1. Runge VM, Clanton JA, Price AC, et al. Dyke Award: evaluation of contrast-enhanced MR imaging in a brain-abscess model. AJNR Am J Neuroradiol. 1985;6:139-147.
2. Runge VM, Clanton JA, Price AC, et al. The use of Gd DTPA as a perfusion agent and marker of blood-brain barrier disruption. Magn Reson Imaging. 1985;3:43-55.
3. Biswas J, Nelson CB, Runge VM, et al. Brain tumor enhancement in magnetic resonance imaging: comparison of signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) at 1.5 versus 3 Tesla. Invest Radiol. 2005;40: 792-797.
4. Runge VM, Biswas J, Wintersperger BJ, et al. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model. Invest Radiol. 2006;41:244-248.
5. Nobauer-Huhmann IM, Ba-Ssalamah A, Mlynarik V, et al. Magnetic resonance imaging contrast enhancement of brain tumors at 3 tesla versus 1.5 tesla. Invest Radiol. 2002;37:114-119.
6. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724.
7. Wintersperger BJ, Runge VM, Biswas J, et al. Brain tumor enhancement in MR imaging at 3 Tesla: comparison of SNR and CNR gain using TSE and GRE techniques. Invest Radiol. 2007;42:558-563.
8. Knopp MV, Runge VM, Essig M, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2004;230:55-64.
9. Colosimo C, Demaerel P, Tortori-Donati P, et al. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children. Pediatr Radiol. 2005;35:501-510.
10. Colosimo C, Knopp MV, Barreau X, et al. A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology. 2004;46:655-665.
11. Kuhn MJ, Picozzi P, Maldjian JA, et al. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg. 2007;106:557-566.
12. Essig M, Tartaro A, Tartaglione T, et al. Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Acad Radiol. 2006;13:744-751.
13. Stuber M, Botnar RM, Danias PG, et al. Contrast agent-enhanced, freebreathing, three-dimensional coronary magnetic resonance angiography. J Magn Reson Imaging. 1999;10:790-799.
14. de Haen C, Anelli PL, Lorusso V, et al. Gadocoletic acid trisodium salt (b22956/1): a new blood pool magnetic resonance contrast agent with application in coronary angiography. Invest Radiol. 2006;41:279-291.
15. Zheng J, Li D, Maggioni F, et al. Single-session magnetic resonance coronary angiography and myocardial perfusion imaging using the new blood pool compound B-22956 (gadocoletic acid): initial experience in a porcine model of coronary artery disease. Invest Radiol. 2005;40:604-613.
16. Deshpande VS, Cavagna F, Maggioni F, et al. Comparison of gradient-echo and steady-state free precession for coronary artery magnetic resonance angiography using a gadolinium-based intravascular contrast agent. Invest Radiol. 2006;41:292-298.
17. Shamsi K, Yucel EK, Chamberlin P. A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: phase II and Phase III clinical trials data. Invest Radiol. 2006;41:822-830.
18. Zheng J, Carr J, Harris K, et al. Three-dimensional MR pulmonary perfusion imaging and angiography with an injection of a new blood pool contrast agent B-22956/1. J Magn Reson Imaging. 2001;14:425-432.
19. Paetsch I, Huber ME, Bornstedt A, et al. Improved three-dimensional freebreathing coronary magnetic resonance angiography using gadocoletic acid (B-22956) for intravascular contrast enhancement. J Magn Reson Imaging. 2004;20:288-293.
20. Michaely HJ, Attenberger UI, Dietrich O, et al. Feasibility of gadofosveset-enhanced steady-state magnetic resonance angiography of the peripheral vessels at 3 Tesla with Dixon fat saturation. Invest Radiol. 2008;43:635-641.
21. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol. 2006;41:213-221.
22. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997;32:780-796.
23. Lorusso V, Arbughi T, Tirone P, et al. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance). J Comput Assist Tomogr. 1999;23(suppl 1):S181-S194.
24. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. Invest Radiol. 2006;41:222-228.
25. Cavagna FM, Lorusso V, Anelli PL, et al. Preclinical profile and clinical potential of gadocoletic acid trisodium salt (B22956/1), a new intravascular contrast medium for MRI. Acad Radiol. 2002;9(suppl 2):S491-S494.
26. La Noce A, Stoelben S, Scheffler K, et al. B22956/1, a new intravascular contrast agent for MRI: first administration to humans-preliminary results. Acad Radiol. 2002;9(suppl 2):S404-S406.
27. Colosimo C, Ruscalleda J, Korves M, et al. Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumineenhanced MRI with routinely used contrast agents at equal dosage. Invest Radiol. 2001;36:72-81.
28. Thilmann O, Larsson EM, Bjorkman-Burtscher IM, et al. Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T. J Magn Reson Imaging. 2005;22:597-604.
29. Bueltmann E, Erb G, Kirchin MA, et al. Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrastenhanced magnetic resonance angiography of the supraaortic vessels at 3 Tesla. Invest Radiol. 2008;43:695-702.
30. Kim JI, Lee JM, Choi JY, et al. The value of gadobenate dimeglumineenhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol. 2008;43:202-210.
31. Sardanelli F, Fausto A, Esseridou A, et al. Gadobenate dimeglumine as a contrast agent for dynamic breast magnetic resonance imaging: effect of higher initial enhancement thresholds on diagnostic performance. Invest Radiol. 2008;43:236-242.
32. Nikolaou K, Kramer H, Grosse C, et al. High-spatial-resolution multistation MR angiography with parallel imaging and blood pool contrast agent: initial experience. Radiology. 2006;241:861-872.
33. Adzamli K, Yablonskiy DA, Chicoine MR, et al. Albumin-binding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model. Magn Reson Med. 2003;49:586-590.